Insmed (IM8N) Stock Overview
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IM8N Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Insmed Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$126.00 |
| 52 Week High | US$184.00 |
| 52 Week Low | US$55.00 |
| Beta | 1.12 |
| 1 Month Change | -9.35% |
| 3 Month Change | -26.74% |
| 1 Year Change | 62.58% |
| 3 Year Change | 563.16% |
| 5 Year Change | 288.89% |
| Change since IPO | 1,008.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| IM8N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.6% | 0.8% | -0.3% |
| 1Y | 62.6% | 4.1% | 4.5% |
Return vs Industry: IM8N exceeded the German Biotechs industry which returned 6.1% over the past year.
Return vs Market: IM8N exceeded the German Market which returned 4% over the past year.
Price Volatility
| IM8N volatility | |
|---|---|
| IM8N Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 13.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: IM8N's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IM8N's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,271 | Will Lewis | www.insmed.com |
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
Insmed Incorporated Fundamentals Summary
| IM8N fundamental statistics | |
|---|---|
| Market cap | €26.77b |
| Earnings (TTM) | -€999.04m |
| Revenue (TTM) | €377.24m |
Is IM8N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IM8N income statement (TTM) | |
|---|---|
| Revenue | US$447.02m |
| Cost of Revenue | US$104.87m |
| Gross Profit | US$342.15m |
| Other Expenses | US$1.53b |
| Earnings | -US$1.18b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 19, 2026
| Earnings per share (EPS) | -5.55 |
| Gross Margin | 76.54% |
| Net Profit Margin | -264.83% |
| Debt/Equity Ratio | 74.4% |
How did IM8N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/17 04:18 |
| End of Day Share Price | 2026/02/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insmed Incorporated is covered by 41 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Eliana Merle | Barclays |
| Anita Dushyanth | Berenberg |